Worldwide Clinical Trials Named Finalist for 2026 SCRS Eagle Award

Site-voted recognition highlights Worldwide's commitment to partnership, collaboration, and the site experience

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials (Worldwide), a global contract research organization (CRO), has been named a finalist for the 2026 Society for Clinical Research Sites (SCRS) Eagle Award, one of the clinical research industry's most respected site-voted recognitions.

Presented annually by SCRS, the Eagle Award recognizes CROs that demonstrate exceptional commitment to advancing clinical research through strong partnerships with research sites. Finalists are selected based on direct feedback and voting from active clinical research sites.

The recognition reflects Worldwide's ongoing investment in strengthening site relationships, improving the site experience, and fostering a culture of collaboration, responsiveness, and transparency across its global clinical development business.

"Being named an SCRS Eagle Award finalist is especially meaningful because the recognition comes unsolicited and directly from the research sites we partner with every day," said Clare Wallis, Executive Vice President, Global Clinical Development, Worldwide Clinical Trials. "Over several years, we have made a deliberate investment in strengthening the site experience by listening to feedback, improving communication, streamlining processes, and ensuring sites feel supported. This recognition is a testament to the dedication of our teams globally and reinforces our commitment to being a responsive, valued partner to sites as we work together to advance clinical research.”

Wallis added: "The timing of this recognition is particularly meaningful. As Worldwide sharpens its focus on clinical development services, our success will continue to depend on strong partnerships. Being named an SCRS Eagle Award finalist reinforces that our site-centric approach and investment in those relationships remain a key part of our strategy."

Strong site relationships remain central to Worldwide's ability to deliver high-quality clinical trials for sponsors and patients globally. As the company continues to invest in growing its Phase II-IV clinical development business, Worldwide remains committed to its extensive global network of external research sites through which it provides healthy volunteer study capabilities.

The recipient of the 2026 SCRS Eagle Award will be announced during the SCRS Global Site Solutions Summit on Saturday, 17 October.

About Worldwide Clinical Trials

Worldwide Clinical Trials (Worldwide) is a global CRO serving development-driven biopharmaceutical companies, with more than 4,400 full-time professionals operating across more than 70 countries. The company delivers therapeutically dedicated expertise in neuroscience, oncology, rare disease, and internal medicine, with comprehensive support across every development phase—from early-stage and first-in-human studies through Phase III registration trials.

The company’s flexible service model—spanning full-service trial management to functional service partnerships through Worldwide Flex—is powered by a people first, partnership driven outsourcing approach that strengthens collaboration, enhances data transparency, and supports more informed decision making. This provides sponsors with tailored, adaptable solutions that keep pace with the evolving demands of clinical research. Learn more at www.worldwide.com.